文献速递血栓与止血造血干细胞移植与细胞治疗

病原体灭活血小板与未处理血小板的止血疗效:一项随机对照试验

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.
PubMed 文献 · Blood · 2018-05-17

该随机非劣效性试验比较核黄素与UVB照射病原体灭活血小板与标准血浆储存血小板在血液恶性肿瘤伴血小板减少患者中预防出血的疗效。意向治疗分析中2级及以上出血比例两组绝对差3%(对照组51% vs 干预组54%,95%CI -6至11,非劣效P=.012),符合非劣效标准;符合方案分析差异8%(对照组44% vs 干预组52%,95%CI -2至18,非劣效P=.19),未达非劣效。干预组输血增量参数约低50%,HLA I类同种抗体产生比例无差异。

要点

  • 意向治疗分析中病原体灭活血小板符合非劣效标准,2级及以上出血绝对差3%。
  • 符合方案分析中两组2级及以上出血差异8%,未达非劣效标准。
  • 干预组输血增量参数约低50%,HLA I类同种抗体产生比例无差异。

核心结论

  • 意向治疗分析中病原体灭活血小板达到非劣效标准,但符合方案分析未显示非劣效。

研究设计与样本

  • 随机非劣效性试验,比较核黄素与UVB照射病原体灭活血小板(干预组)与标准血浆储存血小板(对照组)预防出血的疗效。
  • 2010年11月至2016年4月,469例独特患者随机分配至567个输血治疗期(对照组283个,干预组284个)。
  • 主要结局指标为按世界卫生组织标准定义的2级及以上出血的输血治疗期比例。

主要发现

  • 意向治疗分析中2级及以上出血比例:对照组51% vs 干预组54%,绝对差3%(95%CI -6至11;非劣效P=.012)。
  • 符合方案分析中2级及以上出血比例:对照组44% vs 干预组52%,差异8%(95%CI -2至18;非劣效P=.19)。
  • 干预组输血增量参数约低50%。
  • 两组发生HLA I类同种抗体的患者比例无差异。

局限性

  • 符合方案分析未达到非劣效标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections. However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We conducted a randomized noninferiority trial comparing the efficacy of pathogen-inactivated platelets using riboflavin and UV B illumination technology (intervention) compared with standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia. The primary outcome parameter was the proportion of transfusion-treatment periods in which the patient had grade 2 or higher bleeding, as defined by World Health Organization criteria. Between November 2010 and April 2016, 469 unique patients were randomized to 567 transfusion-treatment periods (283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in grade 2 or higher bleeding in the intention-to-treat analysis: 51% of the transfusion-treatment periods in the control arm and 54% in the intervention arm (95% confidence interval [CI], -6 to 11; P = .012 for noninferiority). However, in the per-protocol analysis, the difference in grade 2 or higher bleeding was 8%: 44% in the control arm and 52% in the intervention arm (95% CI -2 to 18; P = .19 for noninferiority). Transfusion increment parameters were ∼50% lower in the intervention arm. There was no difference in the proportion of patients developing HLA class I alloantibodies. In conclusion, the noninferiority criterion for pathogen-inactivated platelets was met in the intention-to-treat analysis. This finding was not demonstrated in the per-protocol analysis. This trial was registered at The Netherlands National Trial Registry as #NTR2106 and at www.clinicaltrials.gov as #NCT02783313.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood. 2018. PMID: 29773572. doi:10.1182/blood-2018-02-831289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。